利福平治疗持续性肝细胞分泌障碍患者的有效性及安全性

肝脏 ›› 2026, Vol. 31 ›› Issue (3): 420-423.

利福平治疗持续性肝细胞分泌障碍患者的有效性及安全性

彭姗姗, 各廷秋, 何悦, 郑慧, 钟艳丹

210000 南京南京中医药大学附属南京医院(南京市第二医院) 肝病科

收稿日期:2025-04-08 出版日期:2026-03-31 发布日期:2026-05-19
通讯作者: 钟艳丹,Email:zhongyandan@sina.com

Analysis of the efficacy and safety of rifampin in the treatment of patients with persistent hepatocellular secretion disorder

PENG Shan-shan, GE Ting-qiu, HE Yue, ZHENG Hui, ZHONG Yan-dan

Department of Hepatology, Nanjing Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine (Nanjing Second Hospital), Nanjing 210000, China

Received:2025-04-08 Online:2026-03-31 Published:2026-05-19
Contact: ZHONG Yan-dan, Email: zhongyandan@sina.com

摘要/Abstract

摘要： 目的分析利福平治疗持续性肝细胞分泌障碍(persistent hepatocellular secretory failure, PHSF)患者的疗效及安全性。方法选择2022年3月至2024年3月南京市第二医院诊断为PHSF且接受利福平治疗的患者11例。对比利福平治疗前后的实验室数据。结果 11例PHSF患者平均年龄55.4岁,服用利福平前TBil为364.7(276.9,675.7)μmol/L,DBil为279.3(224.3,504.1)μmol/L,TBA为173(94.8,337.0)μmol/L,治疗后TBil下降至 51.5(40.1,192.8)μmol/L、DBil下降至44.5(30.5,139.6)μmol/L、TBA为18.1(13.6,78.5)μmol/L,与治疗前相比,差异有统计学意义(P<0.05)。治疗后有1例患者ALT、AST轻度上升,3例患者出现不同程度的白细胞、中性粒细胞绝对值下降,所有患者接受利福平治疗后肾功能均未见异常。结论利福平治疗PHSF效果良好,安全性较高,但尚需开展随机对照临床研究进一步证实。

关键词: 利福平, 持续性肝细胞分泌障碍, 高胆红素血症

Abstract: Objective To analyze the efficacy and safety of rifampicin in the treatment of 11 patients with persistent hepatocellular secretory failure (PHSF). Methods Patients who were hospitalized in Nanjing Second Hospital from March 2022 to March 2024 and clinically diagnosed with PHSF and received rifampicin treatment were selected. General information, clinical data and laboratory data were collected, and the laboratory data before and after rifampicin treatment were compared. Results The average age of the 11 PHSF patients was 55.4 years old. The average level of total bilirubin before taking rifampicin was 463.15 μmol/L. All patients received rifampicin treatment at a dose of 150~300 mg/d for a course of 3~4 weeks. The changes in relevant indicators before and after treatment were compared. After treatment, TBil decreased to 51.5 (40.1, 192.8) μmol/L, DBil decreased to 44.5 (30.5, 139.6) μmol/L, and TBA decreased to 18.1 (13.6, 78.5) μmol/L, with statistically significant differences compared with those before treatment (P<0.05). After treatment, mild elevation of ALT and AST was observed in one patient, and absolute values of white blood cells and neutrophils decreased to varying degrees was observed in 3 patients. No abnormal renal function was found in all patients after rifampicin treatment. Conclusion Rifampicin shows good efficacy and high safety in the treatment of patients with persistent hepatocellular secretory failure, but randomized controlled clinical studies are still needed for further confirmation.

Key words: Rifampicin, Persistent hepatocellular secretory failure, Hyperbilirubinemia

彭姗姗, 各廷秋, 何悦, 郑慧, 钟艳丹. 利福平治疗持续性肝细胞分泌障碍患者的有效性及安全性[J]. 肝脏, 2026, 31(3): 420-423.

PENG Shan-shan, GE Ting-qiu, HE Yue, ZHENG Hui, ZHONG Yan-dan. Analysis of the efficacy and safety of rifampin in the treatment of patients with persistent hepatocellular secretion disorder[J]. Chinese Hepatolgy, 2026, 31(3): 420-423.

/ 推荐

参考文献

[1] Lindor K D, Gershwin M E, Poupon R, et al. Primary biliary cirrhosis[J]. Hepatology, 2009, 50(1):291-308.
[2] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol, 2017, 67(1):145-172.
[3] 中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021)[J]. 中华肝脏病杂志, 2022, 30(3): 253-263.
[4] van Dijk R, Kremer A E, Smit W, et al. Characterization and treatment of persistent hepatocellular secretory failure[J]. Liver Int, 2015, 35(4):1478-1488.
[5] Shi M, Sheng L, Lian M, et al. Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure[J]. J Gastroenterol Hepatol, 2021, 36(11):3233-3238.
[6] 王芃,刘文迪,胡和平,等. ABCB11基因突变相关性持续性肝细胞分泌衰竭1例[J]. 中华消化杂志, 2024, 44(8):556-559.
[7] Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury[J]. Pharmacogenet Genomics, 2007, 17(1):47-60.
[8] Ellis E, Wagner M, Lammert F, et al. Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin[J]. J Hepatol, 2006, 44(1):243-245.
[9] Geenes V, Chambers J, Khurana R, et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy[J]. Eur J Obstet Gynecol Reprod Biol, 2015, 189:59-63.
[10] Cançado E L, Leitão R M, Carrilho F J, et al. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase[J]. Am J Gastroenterol, 1998, 93(9):1510-1517.
[11] Webb G J, Rahman S R, Levy C, et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study[J]. Aliment Pharmacol Ther, 2018, 47(8):1213-1219.
[12] Bachs L, Parés A, Elena M, et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis[J]. Lancet, 1989, 1(8638):574-576.
[13] El-Karaksy H, Mansour S, El-Sayed R, et al. Safety and efficacy of rifampicin in children with cholestatic pruritus[J]. Indian J Pediatr, 2007, 74(3):279-281.